| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_188564faf644f7669f0b7292e50940a4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N65-00 |
| filingDate |
2005-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28776d6b17d8c1167b7243a716702fe1 |
| publicationDate |
2007-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006063091-A3 |
| titleOfInvention |
Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity |
| abstract |
The disclosure relates to methods of ameliorating or preventing cardiotoxicity caused by anti-neoplastic agent, such as doxorubicin, by administering to a patient oxypurinol, salt or derivatives thereof, before, during or after administration of the anti-neoplastic agent. |
| priorityDate |
2004-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |